-Reuters
Corbus Pharmaceuticals Q1 FY23 R&D Expenses Grow 307% To $13.4M
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a precision oncology company, released financial results for the first quarter of 2023.
Q1 2023 Financial Highlights